Erika Morsia

Scopus Publications

Case Report of a Lymphocytic Variant Hypereosinophilic Syndrome Mimicking T-Cell Lymphoma: A Diagnostic Challenge and Therapeutic Response to Mepolizumab
Elisabetta Rizzo, Erika Morsia, Claudio Agostinelli, Elena Sabattini, Alba Guglielmo, Gaia Goteri, Corrado Zengarini, Michelangelo La Placa, Alessandro Pileri
Australasian Journal of Dermatology, 2026
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG
Iris Amitay-Laish, Keila Mitsunaga, Pablo L Ortiz-Romero, Adèle de Masson, Erika Morsia, Jose A Sanches, Paula A Enz, Vasiliki Nikolaou, Constanze Jonak, Stefanie Porkert, Yael A Leshem, Emily Avitan-Hersh, Emmilia Hodak
British Journal of Dermatology, 2026
Janus kinase inhibitors (JAKis) are increasingly used in patients with mycosis fungoides (MF)/Sézary syndrome (SS), often outside of intentional lymphoma-directed treatment, yet their real-world impact remains uncertain and poorly characterized. Our multicentre experience suggests that disease acceleration may occur in specific clinical contexts, particularly in patients initially diagnosed with dermatitis who were later recognized as having MF/SS while receiving JAKis. It remains uncertain whether this acceleration represents a direct drug-related effect. Observations in post-transplant settings warrant further investigation, particularly given ruxolitinib’s role in this context. However, symptom-focused benefit may be observed in carefully selected patients. Collectively, these findings highlight that the use of JAKis in treating patients with MF/SS should be undertaken with caution.
Characteristics and Outcomes of Progressive Multifocal Leukoencephalopathy in Hematologic Malignancies: A SEIFEM Retrospective Review
Davide Facchinelli, Linda Mazzai, Francesco Marchesi, Francesco Angotzi, Lorena Appio, Elettra Ortu La Barbera, Alessandro Busca, Elisa Buzzatti, Chiara Cattaneo, Marianna Criscuolo, Maria Ilaria del Principe, Eleonora Gugole, Rosalia Malafronte, Mara Memoli, Erika Morsia, Cristina Papayannidis, Monica Piedimonte, Chiara Sartor, Irene Terrenato, Maria Elena Zannier, Livio Pagano
American Journal of Hematology, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study
Francesca Palandri, Monia Marchetti, Elena M. Elli, Alessandro Isidori, Ilaria Gianesello, Chiara Sartor, Novella Pugliese, Maria Di Perna, Erika Morsia, Susanna Gallo, Federico Itri, Vittorio Montefusco, Elena Crisà, Annalisa Biagi, Eloise Beggiato, Olga Mulas, Giulia Benevolo, Elisabetta Abruzzese, Marco Santoro, Alessandra Iurlo, Elisabetta Calistri, Marco Rossi, Bruno Martino, Mario Tiribelli, Carmen Fava, Arbana Dizdari, Monica Crugnola, Andrea Duminuco, Amedeo Votto, Selene Guerzoni, Giovanni Caocci, Fabrizio Pane, Francesco Lanza, Filippo Branzanti, Alessandra Dedola, Flavia Salvatore, Florian H. Heidel, Massimo Breccia, Giuseppe A. Palumbo, Andrew T. Kuykendall, Alessandro Lucchesi, Sara Galimberti
Cancer, 2026
Background Momelotinib, a JAK1 / JAK2 / ACVR1 inhibitor, is approved for treating myelofibrosis with splenomegaly, symptoms, and moderate‐to‐severe anemia. Evidence on its real‐world effectiveness after ruxolitinib failure is limited. Methods This study retrospectively analyzed 221 patients who received momelotinib after ruxolitinib failure by assessing spleen, symptom, and anemia responses, safety, and survival. Logistic regression analyses identified the responses’ predictors. Results Before momelotinib initiation, all patients had received ruxolitinib for a median of 31.5 months and discontinued as a result of resistance (29.9%), intolerance (48.0%), or both (22.1%). At baseline, all patients started at full dose; 97.3% presented with cytopenia, 34.8% presented with large splenomegaly, and 43.9% were highly symptomatic. Most patients (74.7%) switched from ruxolitinib stop to momelotinib within 2 months without tapering, whereas 18.1% waited over a year. After a median exposure of 8.2 months, adverse events occurred in 35.7% of patients, which prompted dose reductions or permanent discontinuation in 12.7% and 19.9% of cases, respectively. At 6 months, 30.0% achieved ≥50% spleen length reduction (SR50), with higher responses in those with prior SR50 to ruxolitinib and shorter transition intervals. Symptom and anemia responses occurred in 39.2% and 63.4% of cases, respectively. After a median follow‐up of 10.3 months, 11 patients (5.0%) progressed to blast phase, and 37 patients (16.7%) died. Two‐year overall and progression‐free survival (including death and blast phase transformation) were 60.9% and 59.0%, respectively. Conclusions Momelotinib demonstrated meaningful clinical benefit and acceptable safety in cytopenic patients pretreated with ruxolitinib, which supports its role after ruxolitinib failure.
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison
Francesca Palandri, Venediktos Kapetanakis, Balázs Dobi, Massimo Breccia, Giuseppe A. Palumbo, Elisabetta Abruzzese, Massimiliano Bonifacio, Mario Tiribelli, Elena Maria Elli, Erika Morsia, Filippo Branzanti, Catherine E. Ellis, Nicholas Ballew, Tom Liu, Kelesitse Phiri, Fulya Sen Nikitas, Shiyuan Zhang, Dwaipayan Patnaik
Annals of Hematology, 2026
The Janus kinase (JAK) inhibitor ruxolitinib is a standard first-line therapy for patients with symptomatic and/or intermediate- to high-risk myelofibrosis (MF). However, the majority of patients discontinue ruxolitinib within 5 years of initiation, mainly due to lack or loss of response and/or therapy-related cytopenias. Additional treatments are needed to improve long-term outcomes, including overall survival (OS). Momelotinib, a JAK1/JAK2/activin A receptor type 1 inhibitor, has demonstrated benefits in reducing anemia and improving symptoms and spleen size in 3 phase 3 trials of patients with intermediate- to high-risk MF (SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM). These studies also provide data on patients who received momelotinib after discontinuing ruxolitinib. In the absence of long-term head-to-head comparisons of momelotinib and other treatments after discontinuation of ruxolitinib, the present study compared OS in patients with ruxolitinib-experienced MF from the momelotinib phase 3 trials vs. those treated with best available therapy (BAT) after ruxolitinib from the RUX-MF retrospective real-world study. The comparison was performed using an unanchored matching-adjusted indirect comparison (MAIC). Additionally, an MAIC of OS was conducted in an anemic subgroup (hemoglobin < 10 g/dL). After adjustment for cross-trial differences, the MAIC results showed a favorable trend for momelotinib vs. BAT, both in the overall population and in the anemic subgroup, with hazard ratios < 1 across all analytical scenarios and all population-matching models with an effective sample size of ≥ 20. This study is a key addition to current evidence surrounding OS post ruxolitinib and highlights the benefit of momelotinib in this setting.
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
Paola Guglielmelli, Massimo Breccia, Francesco Mendicino, Maurizio Martelli, Nicola Di Renzo, Giuseppe A. Palumbo, Monica Crugnola, Maurizio Musso, Silvia Sibilla, Paolo Sportoletti, Elisabetta Abruzzese, Stefana Impera, Alessandra Malato, Sergio Siragusa, Carmine Selleri, Fabrizio Pane, Bruno Martino, Alessandra Ricco, Angelo Gardellini, Anna Marina Liberati, Agostino Tafuri, Maria Langella, Marco Brociner, Paolo Ditonno, Domenico Pastore, Olga Mulas, Barbara Pocali, Marco De Gobbi, Erika Morsia, Giulia Benevolo, Elena Maria Elli, Valerio De Stefano, Antonietta Pia Falcone, Daniele Vallisa, Simona Tomassetti, Francesca Lunghi, Nicola Orofino, Giuseppe Carli, Tiziana Urbano, Alessandro Lucchesi, Marta Brunoventre, Massimiliano Bonifacio, Gianni Binotto, Francesco Cavazzini, Paola Ranalli, Alessandro Allegra, Barbara Anaclerico, Serena Mazzotta, Filippo Gherlinzoni, Mario Tiribelli, Chiara Castiglioni, Marina Landoni, Diletta Valsecchi, Michela Magnoli, Francesco Passamonti, Francesca Palandri
Hematological Oncology, 2026
Ruxolitinib (RUX), a JAK1/2 inhibitor, demonstrated treatment benefits for myelofibrosis (MF) in intermediate‐1 (Int‐1)–risk patients with a significant disease burden; however, the evidence is scarce. This interim analysis investigated the efficacy and safety of ruxolitinib in patients with Int‐1‐risk MF. ROMEI, a multicenter, observational, prospective study, enrolled 508 adult patients with MF receiving ruxolitinib according to approved indications. The present interim analysis was focused on 107 eligible patients in the Int‐1‐risk group. Primary endpoints included changes in symptoms response and health‐related quality of life scores. Secondary endpoints included spleen response evaluation, overall survival, and safety including dosing pattern and dose interruptions. Among the 107 Int‐1‐risk patients with a median age of 63 years, 65.5% were highly symptomatic (total symptoms score: ≥ 20), while the spleen was palpable at ≥ 5 cm and ≥ 10 cm in 74% and 27% of patients, respectively, with baseline EuroQol visual analogue scale (EQ‐VAS) score of 65.1 ± 19.4. After RUX treatment, 42.1% and 43.9% of patients demonstrated a symptom response at 24 and 48 weeks, while 38.9% and 46.8% showed a spleen response at 24 and 48 weeks, respectively. EQ‐VAS increased to 71.8 ± 16.3 at 24 weeks and 69.3 ± 19.2 at 48 weeks. Furthermore, 11.2% and 25.2% of patients reported temporary and permanent discontinuation, respectively with no new adverse events reported. The interim analysis showed that ruxolitinib provided clinical benefits, a manageable safety profile, and improved quality of life for Int‐1‐risk subgroup patients with frequent and sustained responses with acceptable toxicity.
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis
Francesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, Mario Tiribelli, Erika Morsia, Mirko Farina, Giulia Benevolo, Eloise Beggiato, Bruno Martino, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Alessandra Iurlo, Alessandro Isidori, Alessandra Dedola, Emilia Scalzulli, Andrea Duminuco, Daniele Cattaneo, Roberto M. Lemoli, Costanza Bosi, Daniela Cilloni, Monica Bocchia, Fabrizio Pane, Chiara Sartor, Florian H. Heidel, Massimo Breccia, Filippo Branzanti, Giuseppe A. Palumbo, Massimiliano Bonifacio, Elena M. Elli
Cancer, 2026
Background Cytopenia is a common complication in patients with myelofibrosis and may worsen during treatment with ruxolitinib. Methods The RUX‐MF multicenter study evaluated 879 patients treated with ruxolitinib for at least 6 months, categorizing them into four groups based on the evolution of cytopenia: never cytopenic, treatment‐emergent cytopenia, persistent cytopenia, and improved anemia. Results At baseline, 40.6% of patients presented with cytopenia, increasing to 57.8% after 6 months. Baseline cytopenia was associated with significantly reduced median overall survival (OS) compared to noncytopenic patients (3.7 vs. 6.7 years). Prognosis varied notably across groups: patients who remained noncytopenic had the median best OS (8.1 years), whereas those with persistent cytopenia had the worst (3.7 years). Treatment‐emergent cytopenia was linked to intermediate outcomes (5.1 years), with isolated thrombocytopenia showing the poorest prognosis (4.3 years) and anemia a slightly better one (6.1 years). Patients with improved anemia had better survival than those with persistent anemia (5.2 vs. 3.5 years). Symptom response mirrored survival trends, with the best outcomes in noncytopenic and improved anemia groups. Conclusions These findings highlight the prognostic significance of cytopenia dynamics during ruxolitinib therapy and support the use of cytopenia trajectory monitoring as a valuable tool for risk stratification and treatment optimization in myelofibrosis.
FUNCTIONAL HIGH RISK MULTIPLE MYELOMA IN THE ANTI-CD38 QUADRUPLET ERA: REDEFINITION THROUGH REAL WORLD DATA
S. Morè, M. Offidani, L. Corvatta, T. Za, F. Fazio, M. Gherardini, V. Bongarzoni, B. Anaclerico, L. Franceschini, S. Ferraro, L. Cupelli, R. Spadano, L. De Padua, A. Rago, S. Gentili, R. Latagliata, M. Garzia, I. Cordone, V. Mezzanotte, E. Rossi, F. Di Landro, Z. Limongi, E. Morsia, A. Poloni, M.T. Petrucci
Haematologica, 2026
Introduction. Functional high-risk (FHR) multiple myeloma (MM) is currently defined as relapse within 12 or 18 months (mo) from the start of conventional therapy or induction followed by autologous stem cell transplantation (ASCT), irrespective of baseline risk. The introduction upfront of quadruplet regimens (QUAD) incorporating anti-CD38 monoclonal antibodies (mAb) has led to a substantial outcome benefit, particularly in ASCT eligible (TE) patients. Consequently, an update of the current FHR definition is warranted to reflect outcomes achieved with modern QUAD-based approaches. Recently, Costa et al. proposed 36 mo as a new FHR threshold, based on TE MM patients treated with QUAD plus ASCT in the MASTER trial and an institutional cohort.Methods. We conducted a retrospective analysis of TE patients with newly diagnosed MM (NDMM) treated at 12 Italian centers, who were stratified into two groups according to frontline therapy: anti-CD38–based QUAD and triplet regimens without anti-CD38 mAb (TRIPL). Different FHR definitions were assessed by applying distinct progression cutoffs at 12 (FHR12), 18 (FHR18), 24 (FHR24), and 36 months (FHR36) from treatment initiation. Univariate and multivariate Cox regression analysis was performed to assess the best cut-off of PFS and the other factors affecting Overall Survival (OS).Results. The study comprised 404 transplant eligible NDMM patients, of whom 186 received QUAD therapy and 218 TRIPL therapy. QUAD regimens included Dara VTD (162), Dara VCD (12), Dara VRD (10), and Isa KRD (2) whereas TRIPL therapy VTD (203), CyBorD (8) and VRD (7). Baseline characteristics were comparable between the two groups. Among patients receiving QUAD therapy, 28% were older than 65 years, compared with 20% in the TRIPL group. An ECOG performance status ≥2 was reported in 13% and 10% of patients, respectively. ISS stage III was observed in 22% of QUAD and 21% of TRIPL patients, while R ISS stage II–III accounted for 60% and 65%, respectively. High risk cytogenetic abnormalities were present in 26% of QUAD and 30% of TRIPL patients. A platelet count 36 months) was independently associated with inferior OS (HR 4.1, 95% CI 1.6–6.3, p=0.004), together with FISH high risk cytogenetics (HR 2.3, 95% CI 1.2–4.9, p=0.028). Conversely, receipt of QUAD therapy was associated with improved OS (HR 0.6, 95% CI 0.2–0.8, p=0.005).Conclusions. While early progression rates at 12 and 24 months were comparable between treatment groups, a clear separation emerged at 36 months, with a substantially lower cumulative incidence of progression in patients treated with QUAD. In the context of anti-CD38–based QUAD followed by ASCT, FHR MM should be redefined as disease progression occurring within the first 36 months of therapy, providing a more accurate and clinically meaningful framework for risk stratification and future trial design.
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients
Sonia Morè, Massimo Offidani, Laura Corvatta, Silvia Aloisi, Tommaso Za, Francesca Fazio, Martina Gherardini, Velia Bongarzoni, Barbara Anaclerico, Luca Franceschini, Silvia Ferraro, Luca Cupelli, Carmine Liberatore, Francesca Fioritoni, Laura De Padua, Angela Rago, Silvia Gentili, Roberto Latagliata, Mariagrazia Garzia, Giancarlo Discepoli, Antonella Poloni, Erika Morsia, Iole Cordone, Giulia Orlandi, Roberta Merola, Valeria Mezzanotte, Elena Rossi, Francesca Di Landro, Zaira Limongi, Maria Teresa Petrucci
Clinical Lymphoma Myeloma and Leukemia, 2026
We retrospectively analysed cytogenetics by fluorescence in situ hybridization (FISH) in 1.026 patients with multiple myeloma treated in real-world with the aim to establish its role in daily clinical practice. Thirty-seven percent of patients had no FISH data available. Based on median PFS of each cytogenetic abnormality found, we identified 3 group of patients with a significantly different PFS and determined which patients can best benefit from anti-CD38 regimens and double transplant. These findings support cytogenetic testing in all patients at diagnosis. BACKGROUND: Cytogenetics by fluorescence in situ hybridization (FISH) plays an increasing prognostic role in multiple myeloma (MM). METHODS: we analysed cytogenetics and its implications in 1.026 patients treated in real-world from 2019 to 2023. Low-risk (LR) patients had normal cytogenetic or del(13q); intermediate-risk (IR) had t(11;14), hyperdiploidy, gain(1q) or del(1p); high-risk (HR) group had del(17p)/TP53, amp1q21, t(4;14), t(14:16) or t(14;20). Co-existence of 2 high risk abnormalities was named double hit. RESULTS: FISH data were not evaluable in 383 patients (37%). Out of 643 evaluable patients, chromosome 1 alterations were observed in 119 (18.5%), high risk chromosome 14 translocations in 65 (10%), del(17p)/TP53 in 37 (6%) and double-hit in 7 patients (1%). Cytogenetic was normal or hyperdiploid in 252 (39%) and 59 (13%) patients, respectively. Median PFS of LR, IR and HR group were 57.5, 43.2 and 30.5 months, respectively (P < .001). Although anti-CD38 regimens resulted in significantly longer PFS in both TE and NTE pts, in the former significant benefit was documented in the LR and IR group but not in HR group while in the latter only in the LR group. Tandem transplantation did not improve PFS both overall and in the 3 risk groups. Multivariate Cox regression analysis selected ECOG-PS ≥2, R-ISS II-III and our cytogenetic score HR as factors affecting PFS. CONCLUSIONS: in real world, more than one third of MM patients do not have baseline FISH data. Nevertheless, cytogenetics and ECOG PS can be used for prognostic staging and for tailoring therapy.
Chlormethine gel effectiveness as second-line treatment in mycosis fungoides: a single-centre retrospective study
Corrado Zengarini, Alba Guglielmo, Ludovica Vocale, Andrea Filippini, Federico Bardazzi, Erika Morsia, Iria Neri, Martina Mussi, Bianca Maria Piraccini, Alessandro Pileri
Discover Oncology, 2025
BACKGROUND: Chlormethine gel is a promising treatment for early-stage mycosis fungoides (MF) with strong efficacy and manageable side effects. This study evaluates its effectiveness as a second-line treatment in patients unresponsive to prior skin-directed therapies (SDTs) or combined systemic treatments, hypothesising significant therapeutic benefits with manageable adverse reactions. METHODS: A retrospective observational study was conducted from April 2021 to December 2022, including adult patients with histologically confirmed MF who had not responded to at least one prior SDT. Patients received daily chlormethine gel applications, and responses were evaluated at 3, 6, and 12 months using the Modified Severity-Weighted Assessment Tool (mSWAT). Statistical analyses were performed using SPSS ver 26 (IBM), including one-way ANOVA and univariate regression. RESULTS: The study included 21 patients (12 males, 9 females; mean age 61 years). 81% had early-stage MF, and 19% had advanced-stage disease. Chlormethine gel showed a 90% response rate, with 33.3% achieving complete response (CR) and 57.1% partial response (PR). Adverse reactions were primarily contact or irritative dermatitis, which were manageable and did not significantly affect outcomes. Median mSWAT scores significantly reduced from baseline at 3, 6, and 12 months (P = 0.002). CONCLUSIONS: Chlormethine gel appeared to be efficacious and safe as a second-line treatment for MF, including in advanced stages. Despite limitations like small sample size and retrospective design, these findings highlight its potential in combination therapies and the importance of continued treatment for optimal outcomes. Future research should confirm these results in larger, prospective studies.
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?
Sonia Morè, Massimo Offidani, Laura Corvatta, Tommaso Za, Francesca Fazio, Martina Gherardini, Velia Bongarzoni, Barbara Anaclerico, Luca Franceschini, Silvia Ferraro, Luca Cupelli, Carmine Liberatore, Laura De Padua, Angela Rago, Silvia Gentili, Roberto Latagliata, Mariagrazia Garzia, Iole Cordone, Valeria Mezzanotte, Elena Rossi, Francesca Di Landro, Maria Zaira Limongi, Erika Morsia, Antonella Poloni, Maria Teresa Petrucci
Cancers, 2025
Genetic insights into myeloproliferative neoplasms and unusual sites thrombosis
Erika Morsia, Paola Ranalli, Stefano Baldoni, Stefania. Mancini, Sonia Morè, Chiara Cantò, Dorela Lame, Gaetano La Barba, Antonella Poloni, Serena Rupoli, Mauro Di lanni
Annals of Hematology, 2025
Revised “iRR6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, Elena M. Elli, Erika Morsia, Mirko Farina, Mario Tiribelli, Giulia Benevolo, Eloise Beggiato, Bruno Martino, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Elisabetta Abruzzese, Alessandro Isidori, Alessandra Dedola, Emilia Scalzulli, Andrea Duminuco, Luca Tosoni, Alda Strazimiri, Roberto M. Lemoli, Daniela Cilloni, Monica Bocchia, Fabrizio Pane, Chiara Sartor, Florian H. Heidel, Massimo Breccia, Giuseppe A. Palumbo, Andrew T. Kuykendall
Cancer, 2025
Mesenchymal stromal cells from JAK2V617F myeloproliferative neoplasms support healthy and malignant hematopoiesis in a humanized scaffold model in vivo
Alessandra Ferrelli, Syed Mian, Marion Piganeau, Hector Huerga Encabo, Despoina Papazoglou, Giuseppe D'Agostino, Fatihah Mohamad Nor, Manuel Garcia‐Albornoz, Steven Ngo, Linda Ariza‐McNaughton, Erika Morsia, Matteo Giovanni Della Porta, Claire Harrison, Shahram Kordasti, Dominique Bonnet
Hemasphere, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea
Francesca Palandri, Massimo Breccia, Elena M. Elli, Roberto Latagliata, Giulia Benevolo, Erika Morsia, Mario Tiribelli, Francesco Cavazzini, Alessandra D’Addio, Alessia Tieghi, Mirko Farina, Fabrizio Cavalca, Alessandra Dedola, Florian H. Heidel, Giuseppe A. Palumbo, Elena Rossi, Filippo Branzanti, Valerio De Stefano
Leukemia, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, Elena M. Elli, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Mirko Farina, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Elisabetta Abruzzese, Alessandro Isidori, Alessandra Dedola, Alessandra Iurlo, Roberto M. Lemoli, Daniela Cilloni, Monica Bocchia, Florian H. Heidel, Massimiliano Bonifacio, Giuseppe A. Palumbo, Filippo Branzanti
Clinical Lymphoma Myeloma and Leukemia, 2025
Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort
E. Diral, C. Campochiaro, G. Furnari, F. Moretti, J. Ferrari, C. Elena, G. Battipaglia, S. Barbato, A. Vitale, M. Frigeni, F. Crisafulli, M. Frassi, C. Papayannidis, A. D. Romagnoli, C. Cattaneo, A. D'Ambrosio, E. Morsia, P. Musto, G. Rivoli, M. E. Dragani, C. Toffalori, G. M. Bergonzi, G. Scorpio, A. Tomelleri, M. T. Voso, C. Gurnari, L. Vago, L. Dagna, F. Ciceri
British Journal of Haematology, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Francesca Palandri, Massimo Breccia, Erika Morsia, Elena M. Elli, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Mirko Farina, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Alessandro Isidori, Alessandra Dedola, Emilia Scalzulli, Alessia Moioli, Fabrizio Cavalca, Santino Caserta, Andrea Duminuco, Bruno Martino, Roberto M. Lemoli, Daniela Cilloni, Monica Bocchia, Fabrizio Pane, Florian H. Heidel, Massimiliano Bonifacio, Giuseppe A. Palumbo, Filippo Branzanti, Alessandra Iurlo, Elisabetta Abruzzese
Leukemia Research, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
Valerio De Stefano, Francesco Passamonti, Francesca Palandri, Francesco Ramundo, Elena Rossi, Silvia Betti, Lorenzo Fagiolo, Paola Guglielmelli, Davide Pio Abagnale, Novella Pugliese, Daniele Cattaneo, Alessandra Iurlo, Filippo Branzanti, Alessandra Dedola, Hillary Catellani, Alessia Tieghi, Marco Basso, Elisabetta Calistri, Elena Maria Elli, Elena Masselli, Erika Morsia, Giulia Benevolo, Massimo Breccia, Vincenza de Fazio, Maria Di Perna, Monia Marchetti, Marco Santoro, Agostino Tafuri, Chiara Castiglioni, Chiara Rotella, Sergio Siragusa, Alessandro Maria Vannucchi, and
Annals of Hematology, 2025
Pediatric primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: A retrospective analysis and review of the literature
Oluwaseyi Adeuyan, Celine M. Schreidah, Jeffrey W. Craig, Werner Kempf, Erika Morsia, Jose A. Plaza, Christina Mitteldorf, Alessandro Pileri, Larisa J. Geskin, Alejandro A. Gru
Journal of the American Academy of Dermatology, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)
Massimo Breccia, Francesca Palandri, Maurizio Martelli, Francesco Mendicino, Alessandra Malato, Giuseppe A. Palumbo, Silvia Sibilla, Nicola Di Renzo, Elisabetta Abruzzese, Sergio Siragusa, Monica Crugnola, Carmine Selleri, Fabrizio Pane, Paolo Sportoletti, Bruno Martino, Stefana Impera, Alessandra Ricco, Maria Langella, Paolo Ditonno, Giuseppe Carli, Federico Itri, Anna Marina Liberati, Tiziana Urbano, Agostino Tafuri, Vita Polizzi, Domenico Pastore, Erika Morsia, Giulia Benevolo, Giorgia Micucci, Gabriella Farina, Massimiliano Bonifacio, Elena Maria Elli, Angelo Gardellini, Valerio De Stefano, Giovanni Caocci, Antonietta Pia Falcone, Daniele Vallisa, Marco Brociner, Mario Tiribelli, Gianni Binotto, Barbara Pocali, Francesco Cavazzini, Simona Tomassetti, Francesca Lunghi, Mauro Di Ianni, Alessandro Allegra, Barbara Anaclerio, Serena Mazzotta, Nicola Orofino, Filippo Gherlinzoni, Chiara Castiglioni, Marina Landoni, Diletta Valsecchi, Michela Magnoli, Paola Guglielmelli, Francesco Passamonti
Cancer, 2025
Novelties on Multiple Myeloma from the Main 2024 Hematology Conferences
Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
Mediterranean Journal of Hematology and Infectious Diseases, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, Alessandra Dedola, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Mirko Farina, Bruno Martino, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Elisabetta Abruzzese, Alessandro Isidori, Emilia Scalzulli, Domenico D’Agostino, Santino Caserta, Antonella Nardo, Roberto Massimo Lemoli, Daniela Cilloni, Monica Bocchia, Fabrizio Pane, Florian H. Heidel, Giuseppe A. Palumbo, Massimo Breccia, Elena M. Elli, Massimiliano Bonifacio
Annals of Hematology, 2025
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome
Carmelo Gurnari, Elisa Galossi, Eleonora Lumia, Alfonso Piciocchi, Mariadomenica Divona, Elisa Casciani, Francesca Romano, Elisa Diral, Alessandro Tomelleri, Federico Caroni, Antonio Vitale, Gregorio Maria Bergonzi, Annalisa Condorelli, Giorgia Battipaglia, Erika Morsia, Elena Crisà, Paola Triggianese, Arianna Savi, Chiara Cardamone, Matteo Dragani, Giulia Rivoli, Federica Pilo, Davide Firinu, Sara Plebani, Francesco D'Agostino, Alessandro D'Ambrosio, Katja Sockel, Cristina Papayannidis, Silvia Salmoiraghi, Fabrizio Pane, Monica Bocchia, Luca Cantarini, Marco Frigeni, Corrado Campochiaro, Lorenzo Dagna, Raffaella Greco, Fabio Ciceri, Orietta Spinelli, Christian Thiede, Maria Teresa Voso
British Journal of Haematology, 2025
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
Sonia Morè, Irene Federici, Alessandra Bossi, Serena Rupoli, Erika Morsia, Valentina M. Manieri, Attilio Olivieri, Maria T. Petrucci, Francesca Fazio, Chiara Lisi, Silvia Sorella, Adele D. Paoli, Francesca Farina, Anna Mele, Rossella De Francesco, Antonino Greco, Francesca Fioritoni, Carmine Liberatore, Tommaso C. De Toritto, Attilio Tordi, Agostina Siniscalchi, Marino Brunori, Nicola Sgherza, Pellegrino Musto, Angela Amendola, Angelo Vacca, Antonio G. Solimando, Assunta Melaccio, Antonio Palma, Lorella M. A. Melillo, Lucia Ciuffreda, Silvia Gentili, Gabriele Buda, Maria L. Del Giudice, Antonietta P. Falcone, Patrizia Tosi, Simona Tomassetti, Francesco Rotondo, Alessandro Gozzetti, Piero Galieni, Miriana Ruggieri, Ferdinando Frigeri, Rosario Bianco, Alessandra Lombardo, Fabio Trastulli, Laura Corvatta, Carmela Zizzo, Giovanni Duro, Massimo Offidani
Hemasphere, 2025
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study
Francesca Palandri, Elena M. Elli, Erika Morsia, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Massimiliano Bonifacio, Mirko Farina, Bruno Martino, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Elisabetta Abruzzese, Alessandra Iurlo, Alessandro Isidori, Costanza Bosi, Veronica Guglielmana, Marta Venturi, Alessandra Dedola, Michele Loffredo, Gabriele Fontana, Andrea Duminuco, Alessia Moioli, Luca Tosoni, Emilia Scalzulli, Daniele Cattaneo, Roberto M. Lemoli, Daniela Cilloni, Monica Bocchia, Fabrizio Pane, Florian H. Heidel, Nicola Vianelli, Michele Cavo, Giuseppe A. Palumbo, Filippo Branzanti, Massimo Breccia
Cancer, 2024
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations
Alberto Carturan, Sonia Morè, Antonella Poloni, Serena Rupoli, Erika Morsia
Cancers, 2024
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real-world case series
F. Palandri, F. Branzanti, G. Benevolo, E. Beggiato, E. Morsia, A. Dedola, M. Loffredo, G. Fontana, G. A. Palumbo, M. Breccia, M. Tiribelli
British Journal of Haematology, 2024
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report
Valentina Maria Manieri, Massimo Offidani, Debora Capelli, Marco Marzioni, Luca Maroni, Alessandra Filosa, Serena Rupoli, Erika Morsia, Antonella Poloni, Sonia Morè
Annals of Hematology, 2024
Cutaneous T-cell lymphoma care across Europe: insights from the HORIZON programme
Gabriele Roccuzzo, Joana Calvão, Gabor Dobos, Erika Morsia, Pablo Mozas, Elizabeth Peterknecht, Anne M R Schrader, Francesca Zottarelli, Martine Bagot, Rudolf Stadler, Maarten Vermeer, Pietro Quaglino, Julia Scarisbrick
British Journal of Dermatology, 2024
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management
Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Massimo Offidani
Cancers, 2024
Bone Marrow Adipose Tissue
Elena Marinelli Busilacchi, Erika Morsia, Antonella Poloni
Cells, 2024
Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis
Dorela Lame, Michelangelo Pianelli, Shahram Kordasti, Erika Morsia, Attilio Olivieri, Antonella Poloni
Hematology Reports, 2024
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights
Erika Morsia, Elena Torre, Francesco Martini, Sonia Morè, Antonella Poloni, Attilio Olivieri, Serena Rupoli
International Journal of Molecular Sciences, 2024
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort
Carmelo Gurnari, Maria Rosaria Pascale, Antonio Vitale, Elisa Diral, Alessandro Tomelleri, Elisa Galossi, Giulia Falconi, Alessandro Bruno, Francesca Crisafulli, Micol Frassi, Chiara Cattaneo, Diego Bertoli, Massimo Bernardi, Annalisa Condorelli, Erika Morsia, Antonella Poloni, Elena Crisà, Daniela Caravelli, Paola Triggianese, Luisa Brussino, Giorgia Battipaglia, Sara Bindoli, Paolo Sfriso, Federico Caroni, Matteo Dragani, Flavia Mallegni, Federica Pilo, Davide Firinu, Antonio Curti, Cristina Papayannidis, Attilio Olivieri, Sharham Kordasti, Francesco Albano, Fabrizio Pane, Pellegrino Musto, Monica Bocchia, Elisabetta Lugli, Massimo Breccia, Marco Frigeni, Lorenzo Dagna, Raffaella Greco, Franco Franceschini, Corrado Campochiaro, Luca Cantarini, Maria Teresa Voso
American Journal of Hematology, 2024
AL amyloidosis: an overview on diagnosis, staging system, and treatment
Sonia Morè, Valentina Maria Manieri, Laura Corvatta, Erika Morsia, Antonella Poloni, Massimo Offidani
Frontiers in Hematology, 2024
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences
Silvia Alberti Violetti, Marco Ardigò, Paolo Fava, Giuseppe Gritti, Erika Morsia, Francesco Onida, Marco Paulli, Alessandro Pileri, Pietro Quaglino, Serena Rupoli, Miriam Teoli, Pamela Vezzoli
Drugs in Context, 2024
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
Pharmaceuticals, 2023
Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region
Alessandro Pileri, Erika Morsia, Corrado Zengarini, Elena Torre, Gaia Goteri, Pietro Quaglino, Nicola Pimpinelli, Marco Paulli, Stefano A Pileri, Pier Luigi Zinzani, Serena Rupoli
European Journal of Dermatology, 2023
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas
Silvia Uccella, Gaia Goteri, Antonino Maiorana, Valentina Donati, Maria Grazia Tibiletti, Francesca Magnoli, Sofia Facchi, Deborah Merchiori, Erika Morsia, Robel Papotti, Stefania Bettelli, Elisa Forti, Sara Galimberti, Serena Rupoli, Alessandra Filosa, Dimitri Dardanis, Riccardo Bomben, Luca Braglia, Samantha Pozzi, Stefano Sacchi
Human Pathology, 2023
Transfusion dependence is a risk factor for severe infections in myelodysplastic syndromes
M. Pianelli, E. Morsia, D. Lame, A. Carturan, A. Olivieri, A. Poloni
Leukemia Research, 2023
A rare case of aCML associated with CNS involvement and with aggressive clinical course
Dorela Lame, Michelangelo Pianelli, Erika Morsia, Alberto Carturan, Gaia Goteri, Stefania Mancini, Attilio Olivieri, Antonella Poloni
Leukemia Research Reports, 2023
Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints
Serena Rupoli, Gaia Goteri, Erika Morsia, Elena Torre, Federica Giantomassi, Anna Campanati, Anna Maria Offidani, Elisa Molinelli, Giuliano Brandozzi, Stefano Serresi, Alfredo Giacchetti, Leonardo Bugatti, Giorgio Filosa, Giorgio Mozzicafreddo, Marco Simonacci, Attilio Olivieri
Dermatologic Therapy, 2022
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications
Erika Morsia, Elena Torre, Antonella Poloni, Attilio Olivieri, Serena Rupoli
International Journal of Molecular Sciences, 2022
Myeloproliferative Neoplasms with Monocytosis
Erika Morsia, Naseema Gangat
Current Hematologic Malignancy Reports, 2022
Mutations and thrombosis in essential thrombocythemia
Paola Guglielmelli, Naseema Gangat, Giacomo Coltro, Terra L. Lasho, Giuseppe Gaetano Loscocco, Christy M. Finke, Erika Morsia, Benedetta Sordi, Natasha Szuber, Curtis A. Hanson, Animesh Pardanani, Alessandro M. Vannucchi, Ayalew Tefferi
Blood Cancer Journal, 2021
Myelofibrosis: challenges for preclinical models and emerging therapeutic targets
Erika Morsia, Naseema Gangat
Expert Opinion on Therapeutic Targets, 2021
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report
E Morsia, G Goteri, E Torre, KB Garvey, G Discepoli, A Tassoni, S Mancini, F Giantomassi, A Poloni, A Olivieri, S Rupoli
Leukemia Research Reports, 2021
Anticoagulation and vessel recanalization in cirrhotic patients with splanchnic vein thrombosis: A multidisciplinary “real life” experience
Serena Rupoli, Alessandro Fiorentini, Erika Morsia, Gianluca Svegliati-Baroni, Giorgia Micucci, Luca Maroni, Kimberly Blaine Garvey, Alessandro Fiorentini, Alessandra Riva, Lidia Da Lio, Antonio Benedetti, Massimo Offidani, Attilio Olivieri, Tarantino Giuseppe
Vascular Health and Risk Management, 2021
Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients
Naseema Gangat, Erika Morsia, James M. Foran, Jeanne M. Palmer, Michelle A. Elliott, Ayalew Tefferi
British Journal of Haematology, 2020
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
Erika Morsia, Kristen McCullough, Maansi Joshi, Joselle Cook, Hassan B. Alkhateeb, Aref Al‐Kali, Kebede Begna, Michelle Elliott, William Hogan, Mark Litzow, Mithun Shah, Animesh Pardanani, Mrinal Patnaik, Ayalew Tefferi, Naseema Gangat
American Journal of Hematology, 2020
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic
Erika Morsia, Kaaren Reichard, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
American Journal of Hematology, 2020

Erika Morsia

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications